Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tarsus Pharmaceuticals Inc (NQ: TARS )

37.00 +0.15 (+0.41%)
Streaming Delayed Price Updated: 11:10 AM EDT, May 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 115,754
Open 37.00
Bid (Size) 36.82 (4)
Ask (Size) 36.99 (1)
Prev. Close 36.85
Today's Range 36.35 - 37.48
52wk Range 12.57 - 40.40
Shares Outstanding 20,574,104
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire

Performance

YTD
+83.53%
+83.53%
1 Month
+6.51%
+6.51%
3 Month
+30.97%
+30.97%
6 Month
+131.11%
+131.11%
1 Year
+137.33%
+137.33%

More News

Read More
Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) is a Stock Spotlight on 4/15
Via Investor Brand Network
Tarsus to Participate at Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts
Via Benzinga
Earnings Scheduled For February 27, 2024
Via Benzinga
Tarsus Pharmaceuticals's Earnings: A Preview
Via Benzinga
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Announces Pricing of $100.0 Million Public Offering
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Announces Proposed $100.0 Million Public Offering
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Pharmaceuticals - Mixed Projections
Via Talk Markets
Recap: Tarsus Pharmaceuticals Q3 Earnings
Via Benzinga
ICU Medical To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) Making Surprising Moves in Monday Session
Via Investor Brand Network
SoFi Technologies Posts Q4 Earnings, Joins Cardlytics, McGrath RentCorp And Other Big Stocks Moving Higher On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade
Via Investor's Business Daily
Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
HC Wainwright & Co. Maintains Buy Rating for Tarsus Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Big Stocks Moving Higher On Friday: Synaptics Reports Q1 Beat; Joins Lyft, Hologic, Blink Charging
Via Benzinga
Topics Stocks
Exposures US Equities
Why Wynn Resorts Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) Making Surprising Moves in Friday Session
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.